Processa Pharmaceuticals, Inc.
PCSA
$1.99
-$0.17-7.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.58% | 35.04% | 29.19% | 14.33% | 2.82% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.77% | 19.72% | 16.08% | 10.48% | 23.07% |
| Operating Income | 0.77% | -19.72% | -16.08% | -10.48% | -23.07% |
| Income Before Tax | -4.32% | -17.97% | -14.46% | -12.21% | -26.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.32% | -17.97% | -14.46% | -12.21% | -26.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.32% | -17.97% | -14.46% | -12.21% | -26.00% |
| EBIT | 0.77% | -19.72% | -16.08% | -10.48% | -23.07% |
| EBITDA | 0.77% | -19.72% | -16.07% | -10.48% | -23.06% |
| EPS Basic | 90.23% | 86.11% | 82.54% | 71.12% | 55.94% |
| Normalized Basic EPS | 90.23% | 86.11% | 82.54% | 71.12% | 55.94% |
| EPS Diluted | 90.23% | 86.11% | 82.54% | 71.12% | 55.94% |
| Normalized Diluted EPS | 90.23% | 86.11% | 82.54% | 71.12% | 55.94% |
| Average Basic Shares Outstanding | 647.90% | 868.66% | 953.96% | 651.15% | 288.18% |
| Average Diluted Shares Outstanding | 647.90% | 868.66% | 953.96% | 651.15% | 288.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |